Strengthening Vaccine Production and Access to Routine Immunizations in Sub-Saharan Africa | The CommonHealth Live!

Two years since the launch of the African Vaccine Manufacturing Accelerator (AVMA), a financial mechanism that invests in commercially viable manufacturing efforts on the continent, what progress has been made in the effort to produce 800 million vaccines in Africa by 2035? Where are there opportunities for strengthening access to routine immunizations for vulnerable populations, including the 6.7 million zero-dose children in the region, along with those living in fragile and conflict-affected areas? And how can the AVMA, which was developed in response to the region’s challenges in securing access to Covid-19 vaccines during the global pandemic, help build countries’ resilience in the face of current and future disease outbreaks? Please join the CSIS Bipartisan Alliance for Global Health Security for a broadcast conversation with Katherine E. Bliss, Director and Senior Fellow, Immunizations and Health Systems Resilience, with the CSIS Global Health Policy Center, Farrah Losper, Chief Commercial Officer at Biovac and Chairperson of the Board of the African Vaccine Manufacturing Initiative, Folake Olayinka, Director of Immunization, Africa CDC, Shanelle Hall, Principal Advisor to the Director General, Africa CDC, and David Kinder, Head of Development Finance at Gavi, the Vaccine Alliance, regarding the progress of the AVMA and contributions to the immunization landscape in the Africa region.